Asthenic disorders
5Older patient studies assessed fatigue-related symptoms; contemporary confirmatory evidence remains limited.
Mind & sleepSmall molecule
Bromantane (Ladasten)
Adamantane-derived research drug
Studied forFatigue-related disorders5
No FDA-approved product identified for this exact research entry in the targeted review.
What does it do?
An adamantane-based actoprotector discussed for fatigue, motivation and anxiety; Russian clinical reports need contextual appraisal.
Approved & studied uses
Community uses Reported, unvalidated
Cognition
17Motivation, fatigue/asthenia and performance under stress.
Mood / anxiety
17Non-sedating anxiolysis, resilience and mood stability claims.
Physical / immune
17Endurance under heat/exhaustion, immune activity and recovery claims.
Reasons people report using it; these do not establish benefit.17
Evidence limits
View research →A contemporary controlled clinical benefit or human pharmacokinetic result was not verified in this targeted check.5
3 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Key safety information
All risks →Evidence limitation
Product identity and purity cannot be inferred from an online nootropic label.4
No FDA-approved product identified for this exact research entry in the targeted review.
Amino-acid sequence
An exact sequence has not been verified for this formulation.
Reference identity · not independently confirmed17
LengthSmall molecule (adamantane derivative)
Molecular weight · Da306.24 Da
Formula, sequence notation & identity
N-(4-bromophenyl)adamantan-2-amine
Chemical free compound; not an injectable peptide formulation.
Pep-Pedia identity details
Small molecule (adamantane derivative) · 306.24 Da
C16H20BrN (not a peptide — synthetic small molecule)Reference description; checked chemical identity above takes precedence when available.17
Pharmacokinetics
How long does it stay in the body?
Reported half-lifeHuman half-life not verified6
No numerical human elimination estimate was verified for the exact material in this review.
No numerical estimate was found in the checked data or Pep-Pedia profile. A curve would require an unsupported assumption.
What to expect
Study outcomes
Symptom improvement with design limits
The uncontrolled study cannot separate treatment effects from placebo effects or natural variation.5
Reported timelines
Reference & communityDays 1–3 / weeks 1 / 2–3 / 3–4
Reference sequence: stimulation within 1.5–2 hours; energy; full motivation; maximal performance. Reported persistence 2–4 weeks after stopping; not guaranteed.17
These are reported timelines, not a prediction of your response.
Community poll 10 topics · Pep-Pedia snapshot
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Experience
Number of responses to this question: not disclosed.
Effectiveness
The source hides 6 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Primary goal
Number of responses to this question: not disclosed.
Side effects
Number of responses to this question: not disclosed.
Dosage frequency
Number of responses to this question: not disclosed.
How discovered
Number of responses to this question: not disclosed.
Age range
Number of responses to this question: not disclosed.
Gender
Number of responses to this question: not disclosed.
Duration of use
Number of responses to this question: not disclosed.
Would recommend
The source hides 1 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Source & limitations
The source displays “135 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
- Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
- The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
- Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
- Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
- This is a dated snapshot, not a live survey or current recommendation.
Protocols
Doses & schedules
Compare purpose, amount, route, frequency, and duration.
Route
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| Unspecified | 50–100 mg daily | Daily | Asthenic disordersHuman study | 28 days | 5 |
Population 728 analyzed patients with psychoautonomic syndrome Context Uncontrolled multicenter study, not a self-use schedule. Route information Not reported in cited abstract | |||||
| Oral | 50 mg | Once daily in the morning | Standard nootropic/anti-astheniaReference report | 2-4 weeks continuous use recommended | 17 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Oral | |||||
| Oral | 100 mg | Once daily or split 50 mg twice daily | Full therapeutic doseReference report | 2-4 weeks continuous use recommended | 17 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Oral | |||||
| Oral | 25 mgStarting dose | Once daily to assess tolerance | Conservative startReference report | 2-4 weeks continuous use recommended | 17 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Oral | |||||
| Oral | 50-100 mg | Once daily, 1-2 hours before activity | Physical performance enhancementReference report | 2-4 weeks continuous use recommended | 17 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Oral | |||||
| Oral | 50 mg | Once daily for 2-4 weeks, then 1-2 weeks off | Cognitive/mood support cycleReference report | 2-4 weeks continuous use recommended | 17 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Oral | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Oral
- Use period
- 2-4 weeks continuous use recommended
- Break
- 1-2 weeks break between cycles; effects persist during off-period
Reported timing
Morning dosing to align with circadian dopamine patterns; 1-2h before demanding tasks for acute effects
Side effects & safety
Evidence limitation
Product identity and purity cannot be inferred from an online nootropic label.
4Evidence limitation
A contemporary safety profile for unsupervised use was not established in this review.
3Short-term tolerability
Adverse events occurred in 3% and discontinuation in 0.8% in the 28-day study; this does not establish long-term safety.
5Symptoms
Persistent agitation/insomnia, repetitive behavior, racing thoughts, anxiety, mood changes, GI distress, palpitations, chest discomfort or allergy need assessment.
Limitations
No-tolerance/dependence claims do not establish long-term safety.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
9 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
MAOIs
Avoidance reportedTheoretical monoamine accumulation.17
Reference report · Pep-Pedia label: Avoid CombinationSSRIs
Caution reportedUnstudied metabolic interaction.17
Reference report · Pep-Pedia label: Monitor CombinationAdderall / Ritalin
Caution reportedDopaminergic overstimulation.17
Reference report · Pep-Pedia label: Use CautionSelank
Unverified pairingAnxiety rationale.17
Reference report · Pep-Pedia label: SynergisticSemax
Unverified pairingCognition rationale.17
Reference report · Pep-Pedia label: SynergisticNoopept
Unverified pairingProposed dopamine/glutamate complement for motivation and memory; untested.17
Reference report · Pep-Pedia label: CompatibleCaffeine
Unverified pairingCommon use is not safety evidence.17
Reference report · Pep-Pedia label: CompatibleL-tyrosine
Unverified pairingSubstrate rationale.17
Reference report · Pep-Pedia label: CompatibleOther medicines or peptides
Not establishedNo exact-product human interaction study was verified; lack of evidence is not evidence of safety.6
Research contextNo matching interactions. Try another name or filter.
Reconstitution
No product-specific preparation or stability instruction was verified. A dilution calculation does not establish suitability for injection.6
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Oral
The source describes capsules or measured oral material rather than vial reconstitution.
- Form
- Source describes a prepared product
- Reported parameters
- Storage follows the oral product instructions.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported appearanceWhite to off-white crystalline powderReported appearanceThird-party purity testingReported appearanceProper packagingReported variationResearch chemical status (US/EU)Reported variationWADA prohibited substanceReported concernYellowing or clumping
17Available forms
No verified packaging examples included.
Packaging examples, not a market survey. Approved and research products are not interchangeable.
Storage after mixing
Reconstituted research vials
No applicable mixing data
The available sources describe prepared products or do not establish a reconstitution method.17
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Research findings
Limited human dataCompound identity & other names
Bromantane, also called Ladasten, is a small molecule investigated for asthenic disorders. Clinical findings in symptomatic patients do not establish cognitive enhancement in healthy people.
No FDA-approved product identified for this exact research entry in the targeted review.
How it may work
Dopamine-synthesis enzyme and GABA-related mechanisms are described; genomic explanations do not prove clinical benefit.17
Older uncontrolled patient study
A 2010 study analyzed 728 patients with asthenic disorders treated for 28 days. Symptoms improved, but no randomized comparator is described in the abstract.
5Small molecule, not a peptide
Bromantane is an adamantane-derived chemical. Its presence in peptide catalogs does not make peptide reconstitution or peptide half-life assumptions applicable.
3Recent evidence concerns product surveillance
The 2025 laboratory survey investigated unregulated nootropics, including bromantane. It does not establish a treatment effect or a dosing regimen.
4Research areas and evidence gaps
Asthenic disorders. Older patient studies assessed fatigue-related symptoms; contemporary confirmatory evidence remains limited.5
- A contemporary controlled clinical benefit or human pharmacokinetic result was not verified in this targeted check.
- A product-specific research-vial quantity was not independently verified in this review.
Community reports Unvalidated
Pep-Pedia discusses asthenia research.6
Editorial summary, not a measured community survey, clinical protocol or recommendation.
Search coverage and review status
Checked the older uncontrolled patient study and added 2025 product-surveillance research. No newer controlled efficacy trial was verified.
- Checked
- 2026-10-12
- Search
- "bromantane" "2025" study; "Ladasten" 728 patients
- Catalog
- Pep-Pedia ↗ · 12 listed references retained
- Targeted search and selected primary-source checks, not an exhaustive systematic review.
- Preserved bibliography entries marked unreviewed have not had their findings independently verified.
AI-prepared summaries. Independent medical editorial review is pending.
References
Original sources and review status. Open a reference to read its summary.
1Multicenter Asthenia Clinical Trial (2009)Abstract checked
AI-PREPARED SUMMARY
An uncontrolled multicenter study analyzed 728 patients given Ladasten for 28 days. Symptoms improved, but absence of a comparator limits causal interpretation. Adverse events were reported in 3%; 0.8% stopped treatment.
Pep-Pedia bibliography · Checked 2026-10-12
2Treatment of asthenic disorders in patients with psychoautonomic syndrome: results of a multicenter study on efficacy and safety of ladastenAbstract checked
AI-PREPARED SUMMARY
An uncontrolled multicenter study analyzed 728 patients given Ladasten for 28 days. Symptoms improved, but absence of a comparator limits causal interpretation. Adverse events were reported in 3%; 0.8% stopped treatment.
Pep-Pedia bibliography · Checked 2026-10-12
3PubChem: BromantanePrimary source checked
AI-PREPARED SUMMARY
Chemical registry identifies bromantane as an adamantane-derived small molecule, not a peptide.
Small molecule, not a peptide
Bromantane is an adamantane-derived chemical. Its presence in peptide catalogs does not make peptide reconstitution or peptide half-life assumptions applicable.
Additional research · Checked 2026-10-12
4The Occurrence of Illicit Smart Drugs or Nootropics in Europe and Australia and Their Associated Dangers: Results from a Market Surveillance Study by 12 Official Medicines Control LaboratoriesAbstract checked
AI-PREPARED SUMMARY
Bromantane appears in a laboratory market-surveillance study of unregulated nootropic products. This is product analysis, not an efficacy trial.
Recent evidence concerns product surveillance
The 2025 laboratory survey investigated unregulated nootropics, including bromantane. It does not establish a treatment effect or a dosing regimen.
Additional research · Checked 2026-10-12
5Treatment of asthenic disorders in patients with psychoautonomic syndrome: results of a multicenter study on efficacy and safety of LadastenAbstract checked
AI-PREPARED SUMMARY
An uncontrolled multicenter study analyzed 728 patients given Ladasten for 28 days. Symptoms improved, but absence of a comparator limits causal interpretation. Adverse events were reported in 3%; 0.8% stopped treatment.
Older uncontrolled patient study
A 2010 study analyzed 728 patients with asthenic disorders treated for 28 days. Symptoms improved, but no randomized comparator is described in the abstract.
Additional research · Checked 2026-10-12
6Pep-Pedia: Bromantane (Ladasten)Community source checked
AI-PREPARED SUMMARY
Secondary editorial profile and reported practices; not clinical validation.
7Tyrosine Hydroxylase Gene Expression Study (2007)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Rat TH messenger RNA reportedly increased 2–2.5-fold in dopamine-related brain regions.
Reported population / model
Animal
Reported study details
Rat hypothalamus · 10-50mg/kg · 7 days · RT-PCR analysis of TH and AADC mRNA
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
8Pharmacokinetic Profile StudyPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Reported parameters were 42% oral availability, an 11.21-hour half-life and peak times of 2.75 hours in women versus 4 hours in men; metabolites persisted longer.
Reported population / model
Human
Reported study details
100mg single dose · Plasma analysis · Gender-stratified PK parameters
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
9Anxiolytic Properties Without SedationPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Animal anxiety tests improved without the sedative pattern described for benzodiazepines; human comparative safety is not established by these tests.
Reported population / model
Animal
Reported study details
Rat and mouse models · Elevated plus maze and open field tests · Multiple inbred strains
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
10Immunostimulatory Activity StudyPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Mouse assays showed greater phagocytosis and T-cell activity; the clinical significance of these immune changes is uncertain.
Reported population / model
Animal
Reported study details
Mouse · Immune function assays · Acute and chronic dosing
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
11Physical Performance Enhancement (Actoprotector) StudyPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source reports improved exercise capacity under heat and exhaustion; detailed sample size and controlled cardiovascular outcomes are absent from the card.
Reported population / model
Human
Reported study details
Athletes · Physical endurance testing · Heat and physical stress conditions
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
12Toxic effect of single treatment with bromantane on neurological status of experimental animalsPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Mouse assays showed greater phagocytosis and T-cell activity; the clinical significance of these immune changes is uncertain.
Reported population / model
Animal
Reported study details
Mouse · Immune function assays · Acute and chronic dosing
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
13The effect of bromantane on the dopamine synthesis and metabolism in the rat striatumPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Rat TH messenger RNA reportedly increased 2–2.5-fold in dopamine-related brain regions.
Reported population / model
Animal
Reported study details
Rat hypothalamus · 10-50mg/kg · 7 days · RT-PCR analysis of TH and AADC mRNA
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
14The effects of ladasten on dopaminergic neurotransmission and hippocampal synaptic plasticity in ratsLinked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography; findings and bibliographic accuracy have not been independently verified.
Pep-Pedia bibliography · Checked 2026-10-12
15The effect of bromantane on the behavior of inbred mouse strains with different phenotypes of emotional stress reactionPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Animal anxiety tests improved without the sedative pattern described for benzodiazepines; human comparative safety is not established by these tests.
Reported population / model
Animal
Reported study details
Rat and mouse models · Elevated plus maze and open field tests · Multiple inbred strains
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
16Clinical and pharmacokinetic study of the new psychoactive drug LadastenLinked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography; findings and bibliographic accuracy have not been independently verified.
Pep-Pedia bibliography · Checked 2026-10-12
17Pep-Pedia: Bromantane (Ladasten) — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12